Perspective: High-profile court decisions may undercut FDA’s ability to keep drugmakers truthful
Regulatory NewsMichele G. Sullivan
Advertising, Promotion and LabelingMedical DevicesPharmaceuticalsUnited StatesRegulatory NewsMichele G. SullivanAdvertising, Promotion and LabelingMedical DevicesPharmaceuticalsUnited States